Our Authors

Associate Professor Prue Cormie, Australian Catholic University Associate Professor Prue Cormie is an accredited exercise physiologist whose research and clinical work focuses on the application of exercise as medicine for the management of cancer. She aims to enhance the lives of people with cancer through innovative research and effectively translating research into practice. More information on her work is available here: www.iha.acu.edu.au/cancer.4 Articles


Dr Prunella Blinman is a medical oncologist at the Concord Cancer Centre who specialises in the management of thoracic and gastrointestinal cancers. She is also a clinical senior lecturer at the Sydney Medical School, and an active researcher and supervisor of postgraduate students. She enjoys attending the ASCO Annual Meeting for the educational and networking opportunities.4 Articles



Behavioural scientist with extensive experience in cancer clinical research, in particular post-cancer diagnosis supportive care and psycho-oncology.3 Articles


Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.3 Articles


Dr Hilda High is medical oncologist specialising in cancer genetics. She has worked with familial cancer services at the Prince of Wales Hospital, Westmead Hospital and Royal North Shore Hospitals and now works with Sydney Cancer Genetics through rooms at the SAN, in Ultimo in Sydney and via telehealth to rural and regional Australia.3 Articles


A/Prof. Ben Chua is a consultant Radiation Oncologist at GenesisCare Rockhampton and Brisbane (Chermside and Wesley). He qualified obtained his radiation oncology fellowship in 2015 after training in Queensland and regional New South Wales, including a fellowship in head & neck cancer. He also has an interest in complex skin, CNS and haematological malignancies. A/Prof. Chua has a conjoint appointment at the University of Queensland with an active academic portfolio, including over $2m in competitive grant funding, supervision of higher degree students, leadership of clinical trials as a chairperson and principal investigator, publications in international medical journals and presentations at international meetings.2 Articles


BXTAccelyon (BXTA) is the leading low-dose rate brachytherapy (LDR-B) partner to hospitals and clinics worldwide, and distribution partner for the PrecisionPoint™ freehand transperineal prostate biopsy system.2 Articles


Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialisation of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.2 Articles


With a portfolio representing a continuum of activities spanning from prescription drugs and consumer healthcare products to dermo-cosmetics, Pierre Fabre is the second largest dermo-cosmetics laboratory in the world, the second largest private French pharmaceutical group and the market leader in France for products sold over the counter in pharmacies. Its portfolio includes several global brands and franchises, such as Pierre Fabre Oncologie.2 Articles


1 2 3 4 6